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Abstract 
Probiotics are beneficial to gastrointestinal health and have anti-inflammatory properties. An 
experiment was conducted to determine if L. reuteri could protect mice from azoxymethane-
induced colorectal cancer (AOM-CRC). A/J mice were randomly assigned to controls, pre-
treatment, or post-treatment groups. The mice in the groups were injected with 10mg/kg body 
weight of AOM and treated with L. reuteri; given only AOM; given only L. reuteri; or given 
neither AOM nor L. reuteri. At the end of a 26-week latency period, the mice were euthanized, 
dissected, and colons examined for tumors. L. reuteri did not protect animals against tumor 
formation. However, L. reuteri treatment had a significant effect on tumor number when the 
mice were segregated by gender (p = 0.014). There was no significant effect of regimen on tumor 
number (p = 0.667) or tumor size (p = 0.197). Ultimately, L. reuteri exhibited probiotic 
properties as a potential prophylactic treatment for colitis. 
Keywords: Colorectal Cancer, Azoxymethane, Lactobacillus reuteri  
 
Introduction 
According to the American Cancer Society (2014), colorectal cancer (CRC) remains the 3rd most 
frequently diagnosed cancer in the United States, behind lung cancer (the leading cause of 
cancer-related deaths for both genders, and behind prostate cancer (men) and breast cancer 
(women).  An emerging area of active research is the connection between the commensal flora in 
the gastrointestinal tract, host genetics, and cancer biology/pathogenesis. Twenty percent of CRC 
is caused by hereditary factors (Fearnhead et al., 2002). Another 20% of CRC can be traced to 
chronic inflammation caused by parasites, harmful bacteria and viral infections (Venning et al., 
2013). The remaining determinants linked to CRC are related to environmental factors and 
lifestyle choices (Chan et al., 2010). Diet is a major factor that can modulate the health of the 
gastrointestinal tract and can alter the gut microbial composition of an organism (De Filippo et 
al., 2010). Probiotics are naturally found in the gut of animals but in varying amounts depending 
on the organism. Consuming additional probiotics could enhance the diversity of the commensal 
flora and the health of the gut (Barbara et al., 2005), and could potentially prove 
chemotherapeutic for organisms with CRC. The objective of this study was to determine if 
Lactobacillus reuteri (L. reuteri), a common inhabitant of the gastrointestinal tracts of most 
mammals, could modulate the severity of CRC in mice injected with the colon-specific, chemical 
carcinogen, azoxymethane (AOM).  
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Literature Review 
CRC is the third most commonly diagnosed cancer in the United States. In 2014,136,830 people 
were diagnosed with CRC, and of these, 50,310 were expected to die (American Cancer Society, 
2014). The colon is made up of different segments that include the ascending colon, transverse 
colon, descending colon, sigmoid colon, and the rectum. The most proximal segment is the 
ascending colon and the more distal segments are the descending and sigmoid colon (American 
Cancer Society, 2014). The majority of CRC cases are not caused by single genetic determinants, 
but are considered sporadic cancers (Frank et al., 2007). Of all sporadic colonic tumors, 75% are 
found in the descending colon (Li and Lai, 2009); however, CRC that is found in the more 
proximal segments of the colon has a better prognosis (Loupakis et al., 2015).   
 
The risk factors for CRC include age, gender, physical activity, heredity, and diet. The older a 
person is, the greater the likelihood that he/she will develop cancer of the colon. Men develop 
CRC at a higher rate than women (American Cancer Society, 2014; 2011). The incorporation of 
more physical activity into one’s daily life reduces one’s chances of developing CRC (Tárraga 
López et al., 2014). Eighty percent of all colon cancers are not genetically linked (Frank et al, 
2007), and most of these tumors are caused by small aberrations in the DNA paired with one of 
the aforementioned risk factors (Bissahoyo et al., 2005). Diet is another very important factor in 
influencing the development of CRC (Parnaud et al., 1997). Increased fruit and vegetable intake 
lessens the chances of developing colon cancer (Koushik et al., 2007) and increased consumption 
of meat cooked at high temperatures increases the risk of developing CRC (Kim, 2013).  
 
Studies involving germfree mice revealed that bacteria are co-factors in the development of both 
inflammatory bowel disease (IBD) and colon tumors, inducing inflammation and tumor 
formation in certain genetic mouse models of CRC due to peroxidative stress (Chu et al., 2004). 
The inflammation which leads to CRC is reportedly caused by inappropriate responses to 
gastrointestinal (GI) bacteria (Sellon et al., 1998). This inflammation is implicated in ulcerative 
colitis-related CRC, as this form of IBD increases cancer risk 20-30% (Rufo and Bousvaros, 
2006). Microflora can regulate epithelial cell signaling for immune reactions. (Chu et al., 2004) 
and skew an immune response in a way that either potentiates or protects animals from disease. 
Lactobacilli have been found to induce gene transcription in epithelial cells (Zoetendal et al, 
2002); induce secretion of antibodies like IgA (Zoetendal et al., 2002), and usurp the host 
epithelial cell machinery to provide for their own needs (Mahida, 2004).  Bacteria can even 
regulate the production of cytokines and chemokines like Nf-kappa-B and IL-8 (Mahida, 2004), 
as well as IL-1, IL-6, IL-10, IL-12, and TNF-alpha (Karlsson et al., 2004; Raz et al., 2007).   
 
The intestinal microflora can determine the pre-immune antibody repertoire in rats and modulate 
the development of the gut-associated lymphoid tissue (GALT) via stress responses (Rhee et al., 
2004). Additionally, bacteria contribute to the regulation of intestinal angiogenesis and the 
induction of oral tolerance. GI commensal organisms live in a symbiotic association with the 
lumen or mucosal layers of the GI tract, though a few species, such as the Lactobacilli, live 
attached to the epithelium. Some of these organisms are involved in promoting GI and immune 
system homeostasis, as well as tissue and immune system development (Guarner, 2006). Lack of 
proper interactions between these bacteria and their host could disrupt this delicate ecosystem 
and lead to disease (Falk et. al., 1998). However, certain species of probiotic organisms have 
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been shown to offer protection for diseases like CRC (Fukui et al., 2001) and IBD (Shultz et al., 
2002).  
 
Probiotics are believed to confer anti-carcinogenic properties like decreased inflammation, 
enhanced immune function, and anti-tumorigenic activity by a number of mechanisms, including 
inhibiting growth of colonic cells, increasing the production of conjugated linoleic acids, 
increasing concentrations of beneficial bacteria, reducing colorectal proliferation and the 
capacity of fecal water to induce necrosis, reducing the levels of pathogenic micro-organisms, 
binding to potential food carcinogens, improving epithelial barrier function, and reducing 
bacterial enzymes which hydrolyse pre-carcinogenic compounds, such as beta-glucuronidase 
(Lee et al., 2007; Ewaschuk et al., 2006; Geier et al., 2006; Rafter et al., 2007). Lorea-Baroja et 
al., (2007) found that consumption of a probiotic yogurt, supplemented with L. reuteri and other 
organisms, led to anti-inflammatory effects in the host. L. reuteri and L. fermentum were found 
to have immunomodulatory effects in a trinitrobenzenesulfonic acid model of rat colitis (Peran et 
al., 2007). Still, not enough intervention studies have been conducted to evaluate the efficacy of 
probiotics in GI diseases like IBD and CRC (Bergonzelli et al., 2005). 
 
IL-10-/- animals develop spontaneous colitis under specific-pathogen-free (SPF) conditions but 
remain disease-free if kept germfree (Schultz et al., 2002; Ruiz et al., 2006). This is due to 
aggressive T lymphocyte responses to the enteric flora (Cong et al., 1998).  The microflora has 
also been implicated as the causal factor in other models of colitis (Chu et al., 2004; Esworthy et 
al., 2003). So the microflora is key in the development of colitis, but among the microflora 
certain members were found to protect mice against the disease (Shultz et al., 2002). Colitis in 
129SvEv IL-10-/- animals could be prevented by pre-treating the animals with L. plantarum 299V 
(Schultz et al., 2002).  
 
In a comparative study of mice with and without colitis (Pena et al., 2004), it was found that IL-
10-/- mice that developed colitis were largely colonized by species of L. johnsonii, L. reuteri, L. 
vaginalis and L. paracasei were found in the mice that did not develop colitis and L. reuteri was 
found to have an immuno-inhibitory effect on TNF-alpha production, which could be related to 
the lack of colitis in the animals tested. L. reuteri was later found to reduce H. hepaticus-induced 
IBD in this same mouse model (Pena et al., 2005). Casas and Dobrogosz (2000) found that L. 
reuteri is the only Lactobacillus species that inhabits the gastrointestinal tract of all vertebrates 
and mammals. They also reported that there is host-specificity to how the L. reuteri strains 
function as probiotics. L. reuteri was demonstrated to protect against viral, fungal, and protozoan 
infections as well as to improve GI biology and morphology. The broad spectrum activity of L. 
reuteri led us to believe it might prove therapeutic against experimental CRC and/or IBD. 
 
Based on the above, the study sought to determine whether the probiotic organism L. reuteri 
would abrogate carcinogenesis in AOM-injected A/J mice (AOM-CRC), which show a high 
penetrance and multiplicity for experimental colon cancer in response to AOM. Consequently, 
the authors assessed the chemotherapeutic properties of L. reuteri in a mouse model of CRC 
disease. 
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Materials and Methods 
Bacterial Strains  
Pure cultures of L. reuteri isolates 4000 and 4020 were provided by Walter Dobrogosz and 
Norris Carbal (North Carolina State University, Raleigh, NC and BioGaia, Inc. Raleigh, NC 
27617). L. reuteri strains were grown in stationary Man, Rogosa, and Sharpe (MRS) broth 
(Remel Products,  Lenexa, KS 66215), under anaerobic conditions at 27 °C.  
 
Mice  
A/J mice (Jackson Labs, Bar Harbor, ME, 04609) were housed under specific pathogen free 
(SPF) conditions in the Department of Lab Animal Medicine (DLAM) at the University of North 
Carolina at Chapel Hill (UNC-CH). The animals were maintained on standard sterilized chow 
and water. Animals were introduced into the study at 8-16 weeks old. A total of 34 animals were 
used in the study, with 12 of those being female animals. The mice were distributed across 13 
cages. 
 
Experimental Colon Cancer 
Probiotics are known to be beneficial to gastrointestinal health and when added to the diet can be 
used as a preventive measure for GI-related illnesses. In order to investigate whether L. reuteri 
could protect mice from azoxymethane-induced colorectal cancer (AOM-CRC), AOM-
susceptible mice were given probiotic supplementation and tumor incidence, location, and 
multiplicity were measured using the AOM-CRC model. The AOM-CRC model was chosen, 
because it is the model that most closely recapitulates sporadic human colon cancer (Chen and 
Huang, 2009). 
 
A/J mice that were more than 2 months old were randomly assigned to control, pre-treatment, or 
post-treatment groups. The pre-treatment, post-treatment, and probiotic-only control groups 
contained six mice each. The nothing-added control and the L. reuteri control group contained 4 
mice each. Pre-Treatment groups were given 108/L. reuteri colony-forming units (CFU) per 
mouse/day by adding the organisms to water bottles. Water bottles were changed every 2-3 days 
to preserve consistent L. reuteri numbers across cages. Two weeks later, all mice earmarked for 
treatment were injected intraperitoneally once a week for four weeks with 10mg/kg body weight 
of AOM (Sigma-Aldrich Corp. St. Louis, MO) suspended in 1X Phosphate Buffered Saline 
(PBS).  
 
At 13 weeks, the animals in the post-treatment group were started on the L. reuteri probiotic 
regimen. The AOM control animals were given the probiotic (L. reuteri) but were not injected 
with AOM. L. reuteri control animals were injected with AOM but not given the probiotic (L. 
reuteri). Negative control animals were neither injected with the AOM nor treated with the L. 
reuteri. At the end of a 26-week latency period, all mice were euthanized by isoflourine overdose 
and dissected. Using the procedure previously described by Bissahoyo et al., (2005), colons were 
removed, flushed with PBS, splayed open, and scored for tumors. Colons were then rolled from 
the distal to proximal end, and preserved in 10% Neutral Buffered Formalin. Processed samples 
were dehydrated in 70% ethanol then paraffin embedded. Tissue blocks were sectioned (6 µm) 
and stained with hemotoxylin and eosin for histopathological analysis. 
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Statistical Analysis 
It was hypothesized that the anti-inflammatory properties of L. reuteri would reduce the 
incidence of colorectal cancer in A/J mice. Data were subjected to ANOVA (StatView). Values 
are presented as the mean of n experiments + standard deviation.  All values with a p value < 
0.05 were considered significant. Treatment, gender, cage, cage density, mouse age, treatment 
regimen, weight, and colon length were determined and assessed for their role in modulating 
tumor size, and tumor location. 
  
Results and Discussion 
All bacterial species were successfully cultured and used to associate the mice (data not shown). 
Bacterial identities were verified by gram-staining and growth in differential media. The mice 
which did not receive AOM-injections did not develop any detectable tumors (Table 1).  
 
The mice treated with L. reuteri alone did not evidence any increase in tumor incidence 
compared to other animals in other treatment groups (data not shown) but did reduce 
inflammation in this experimental model (data not shown). Surprisingly, L. reuteri 
supplementation did not significantly alter morbidity in AOM-treated animals as measured by 
tumor number (Figure 1), mortality (Figure 2), tumor penetrance (Figure 3), or tumor 
multiplicity (Figure 4), although there was a significant effect of gender on tumor penetrance and 
multiplicity (Figure 3, Figure 4), especially in animals which did not receive any probiotic. Total 
tumor numbers (p = 0.834), tumor size (p = 0.237) and multiplicity (p = 0.237) were not 
significantly different for L. reuteri-treated animals compared to AOM-only treated animals 
(data not shown). 
There was a significant effect of gender on tumor number, with females having a higher tumor 
burden than males (p = 0.014; Figure 1). This could be due to slight differences in the weights of 
females vs. male mice or it could be due to hormonal differences between the mice. The females 
were nulliparous and were prevented from mating, but there may have still been gender-specific 
physiological differences in the mice that confounded the data collected. However, gender did 
not affect tumor size (p = 0.920) nor tumor location (p = 0.211; data not shown). Age was not a 
significant factor in tumor number (p = 0.528) nor was tumor size (p = 0.070), but age exerted a 
significant effect on tumor location (p = 0.003), with younger mice having more proximal tumors 
compared to older animals (data not shown). The relevance of this finding is not clear and 
additional studies need to be conducted to gain more insight into how this affects cancer 
prognosis. However, distal tumors are associated with worse prognosis (Gervaz et al., 2001) 
compared to proximal tumors. There was no effect of regimen (no treatment vs. pre-treatment, vs. 
post-treatment) on tumor number (p = 0.667, data not shown) or tumor size (p = 0.197; data not  
shown). This may indicate that the dosage used in this study might need to be increased in order 
to see a significant effect of the probiotic supplementation. 
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Table 1. Animals used in the AOM-CRC L. reuteri Study 
 
*Treat. Gender  Cage Weight  Tumors Size Location  Density  Age   Colon L. Regimen 
      (g)           (mm) (mm)           (mon)   (mm) 
1. R F D001 27.600 5.000 2.200 36.000 3.000 3.000 115.000  PRE 
2. R F D001 22.300 2.000 3.750 22.500 3.000 3.000 80.000  PRE 
3. R F D001 25.400 4.000 3.130 18.750 3.000 3.000 90.000  PRE 
4. C F D002 20.800 2.000 2.500 22.500 1.000 3.000 95.000  CON 
5. R M D003 32.100 1.000 1.500 0.000 3.000 3.000 90.000  PRE 
6. R M D003 32.100 2.000 3.000 10.000 3.000 3.000 105.000  PRE 
7. R M D003 26.400 0.000 0.000 . 3.000 3.000 80.000  PRE 
8. C M D004 25.100 0.000 0.000 . 5.000 3.000 60.000  CON 
9. C M D004 25.400 0.000 0.000 . 5.000 3.000 95.000  CON 
10. C M D004 23.400 0.000 0.000 . 5.000 3.000 85.000   CON 
11. C M D004 24.600 1.000 2.000 25.000 5.000 3.000 100.000  CON 
12. C M D005 20.300 2.000 3.000 15.000 2.000 3.000 95.000  PRE 
13. R M D005 24.400 1.000 3.500 15.000 2.000 3.000 80.000  PRE 
14. R M D006 25.000 2.000 2.500 37.500 5.000 4.000 105.000  POST 
15. R M D006 25.100 0.000 0.000 . 5.000 4.000 95.000  POST 
16. R M D006 32.800 0.000 0.000 . 5.000 4.000 90.000  POST 
17. R M D006 29.900 0.000 0.000 . 5.000 4.000 90.000  POST 
18. R M D006 27.500 0.000 0.000 . 5.000 4.000 100.000  POST 
19. C M D007 28.800 0.000 0.000 . 2.000 4.000 105.000  CON 
20. C  F D008 25.200 0.000 0.000 . 1.000 4.000 115.000  CON 
21. R F D11 22.300 2.000 1.500 37.500 5.000 4.000 95.000  POST 
22. R F D11 22.800 1.000 2.000 30.000 5.000 4.000 105.000  POST 
23. R F D11 21.600 3.000 2.830 30.000 5.000 4.000 115.000  POST 
24. C M D12 27.500 0.000 0.000 . 1.000 3.000 105.000  CON 
25. R M B571 27.800 2.000 2.500 10.000 4.000 3.000 85.000  PRE 
26. R M B571 26.800 2.000 3.250 30.000 4.000 3.000 105.000  PRE 
27. R M B571 27.300 0.000 0.000 . 4.000 3.000 100.000  PRE 
28. C M B579 26.400 0.000 0.000 . 3.000 3.000 110.000  CON 
29. C M B579 27.000 0.000 0.000 . 3.000 3.000 80.000  CON 
30. C M B579 24.500 1.000 3.000 15.000 3.000 3.000 110.000  CON 
31. C F B580 18.900 7.000 2.790 17.900 4.000 3.000 85.000  CON 
32. C F B580 25.900 4.000 3.380 22.500 4.000 3.000 50.000  CON 
33. C F B580 21.600 3.000 3.130 13.300 4.000 3.000 90.000  CON 
34. C F B580 23.500 2.000 2.750 7.500 4.000 3.000 85.000  CON 
 
*    Treat.=treatment (R=L. reuteri; C=Control) ,  Gender, Cage, Weight in grams,  # of Tumors, Size in mm,  
Location (mm from distal  end),  Density (number of animals/cage),  Age (in months), Colon L=colon length in 
mm, Regimen 
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Figure 1. Effect of Gender Supplementation on Tumor Number 
When compared to the control mice with normal mucosa (Figure 5), mice given AOM injections 
developed adenomas with high grade dysplasia (Figure 6), and gastrointestinal intra-epithelial 
neoplasia with high grade dysplasia (Figure 7).  Mice treated with L. reuteri-only did not develop 
any tumors. These data confirmed that AOM causes colon-specific tumor in the A/J mouse strain 
after the 26-week latency. The development of dysplastic lesions (both low and high grade) as 
well as frank tumors, suggests that the AOM injection protocol models the step-wise cancer 
progression seen in human CRC.   
 
 
Figure 2. Effect of L. reuteri supplementation on Mortality Rate, by treatment 
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Figure 3. Effect of L. reuteri supplementation on Tumor Penetrance, by Gender, by Treatment 
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Figure 4. Effect of L. reuteri supplementation on Tumor Multiplicity, by Gender, by Treatment 
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Figure 5. Normal mucosa, submucosa and muscularis of colon 
 
 
Figure 6. Adenoma of colon, papillary, with high grade dysplasia, group 129 SvEv ASF, 100x 
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Figure 7. Gastrointestinal intraepithelial neoplasia, colon, with high grade dysplasia, group 129 
SvEv GF  (100x) 
Conclusion 
It was determined that L. reuteri was not effective in reducing colon cancer severity in our 
mouse model, but that gender had a significant effect on AOM-induced colorectal cancers. Age 
had a significant effect on tumor location, with older age being associated with worse prognosis.  
Additional studies regarding dosage and routes of administration should be conducted. It may be 
that a higher dosage of the L. reuteri might have proven more effective. It may also be important 
to start the administration of L. reuteri during development as a strategy (Ex. beginning the 
supplementation at a neonatal stage). A future goal of the researchers is to test the efficacy of 
other lactobacillus strains in this and other experimental models of CRC. The potential of L. 
reuteri for use as probiotic therapy in GI diseases warrants further investigation. 
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